{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T19:25:22Z","timestamp":1746213922790},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Disease-a-Month"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.disamonth.2012.01.007","type":"journal-article","created":{"date-parts":[[2012,3,23]],"date-time":"2012-03-23T19:15:39Z","timestamp":1332530139000},"page":"168-176","source":"Crossref","is-referenced-by-count":7,"title":["Chronic Myelogenous Leukemia for Primary Care Physicians"],"prefix":"10.1016","volume":"58","author":[{"given":"Sara R.","family":"Torgerson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rami Y.","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehab","family":"Atallah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.disamonth.2012.01.007_bib1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.disamonth.2012.01.007_bib2","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1056\/NEJMct071828","article-title":"Bcr-abl tyrosine kinase inhibitors for chronic myelogenous leukemia","volume":"357","author":"Schiffer","year":"2007","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.disamonth.2012.01.007_bib3","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.disamonth.2012.01.007_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1365-2141.1997.d01-1982.x","article-title":"Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period","volume":"96","author":"Savage","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.disamonth.2012.01.007_bib5","first-page":"1013","article-title":"Chromosome studies in human leukemia","volume":"27","author":"Nowell","year":"1961","journal-title":"J Natl Cancer Inst"},{"issue":"5405","key":"10.1016\/j.disamonth.2012.01.007_bib6","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.disamonth.2012.01.007_bib7","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nm0596-561","article-title":"Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of bcr-abl positive cells","volume":"2","author":"Druker","year":"1996","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.disamonth.2012.01.007_bib8","first-page":"138","article-title":"Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"14","author":"Atallah","year":"2007","journal-title":"Curr Opin Hematol"},{"issue":"11","key":"10.1016\/j.disamonth.2012.01.007_bib9","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.disamonth.2012.01.007_bib10","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"New Engl J Med"},{"issue":"22","key":"10.1016\/j.disamonth.2012.01.007_bib11","first-page":"1126","article-title":"International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with Imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"issue":"7","key":"10.1016\/j.disamonth.2012.01.007_bib12","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.disamonth.2012.01.007_bib13","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.disamonth.2012.01.007_bib14","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.disamonth.2012.01.007_bib15","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1182\/blood-2007-04-038943","article-title":"How I treat chronic myeloid leukemia in the imatinib era","volume":"110","author":"Goldman","year":"2007","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.disamonth.2012.01.007_bib16","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1182\/blood-2010-08-302679","article-title":"Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations","volume":"117","author":"Jabbour","year":"2011","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.disamonth.2012.01.007_bib17","doi-asserted-by":"crossref","first-page":"5600","DOI":"10.1182\/blood-2010-11-318949","article-title":"Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib","volume":"117","author":"Cortes","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.disamonth.2012.01.007_bib18","first-page":"1200","article-title":"Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib","volume":"22","author":"Hochhaus","year":"2008","journal-title":"Leucemia"},{"issue":"4","key":"10.1016\/j.disamonth.2012.01.007_bib19","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.disamonth.2012.01.007_bib20","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1182\/blood-2010-10-309807","article-title":"Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy","volume":"117","author":"Ibrahim","year":"2011","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.disamonth.2012.01.007_bib21","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve Complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.disamonth.2012.01.007_bib22","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1182\/blood-2010-07-294330","article-title":"Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib","volume":"117","author":"Haouala","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.disamonth.2012.01.007_bib23","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1345\/aph.1M715","article-title":"Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity","volume":"44","author":"Bilgi","year":"2010","journal-title":"Ann Pharmacother"},{"issue":"7","key":"10.1016\/j.disamonth.2012.01.007_bib24","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1200\/JCO.2005.04.6557","article-title":"Pregnancy among patients with chronic myeloid leukemia treated with imatinib","volume":"24","author":"Ault","year":"2006","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.disamonth.2012.01.007_bib25","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1200\/JCO.2010.31.3619","article-title":"Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia","volume":"29","author":"Cortes","year":"2011","journal-title":"J Clin Oncol"}],"container-title":["Disease-a-Month"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502912000089?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502912000089?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,25]],"date-time":"2018-11-25T00:54:35Z","timestamp":1543107275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011502912000089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0011502912000089"],"URL":"https:\/\/doi.org\/10.1016\/j.disamonth.2012.01.007","relation":{},"ISSN":["0011-5029"],"issn-type":[{"value":"0011-5029","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}